Fig. 3 | Eye

Fig. 3

From: Teprotumumab, an insulin-like growth factor-1 receptor antagonist antibody, in the treatment of active thyroid eye disease: a focus on proptosis

Fig. 3

Study design. ǂExcluding local supportive measures and oral steroids if the maximum cumulative dose is less than 1000 mg methylprednisolone or equivalent. There must be at least 6 weeks between last administration of steroids and study randomization. aOne patient underwent randomization and withdrew prior to dosing. bIn total, 37 patients completed therapy, 5 discontinued teprotumumab due to an adverse event. cIn total, 39 patients completed therapy, 6 discontinued placebos (one had an adverse event and five had other reason)

Back to article page